Role of cytokines in the pathogenesis of inflammatory bowel disease

Annual Review of Medicine

Volumn 51, Issue , 2000, Pages 289-298

  Papadakis, Konstantinos A ^a   Targan, Stephan R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crohn's disease; Interleukin 10; Treatment; Tumor necrosis factor ; Ulcerative colitis

Indexed keywords

CYTOKINE; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL TRIAL; CROHN DISEASE; ENTERITIS; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; FORECASTING; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; INTESTINAL MUCOSA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034005581     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.51.1.289     Document Type: Review

References (28)

1. 1. Papadakis KA, Targan SR. 1999. Current theories on the cause of inflammatory bowel disease. Gastroenterol. Clin. N. Am. 28:283-96
2. 2. Fiocchi C. 1998. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182-205
3. 3. Shanahan F, Targan S. 1992. Medical treatment of inflammatory bowel disease. Annu. Rev. Med. 43:125-33
4. 4. Sartor RB. 1994. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 106:533-39
5. 5. Elson CO. 1996. The basis of current and future therapy for inflammatory bowel disease. Am. J. Med. 100:656-62
6. 6. Hagenbaugh A, Sharma S, Dubinett SM, et al. 1997. Altered immune responses in IL-10 transgenic mice. J. Exp. Med. 185: 2101-10
7. 7. Plevy SE, Landers CJ, Prehn J, et al. 1997. A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J. Immunol. 159:6276-82
8. 8. Fuss IJ, Neurath M, Boirivant M, et al. 1996. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157: 1261-70
9. 9. Monteleone G, Biancone L, Marasco R, et al. 1997. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112:1169-78
10. 10. Targan SR, Hanauer SB, van Deventer SJH, et al. 1997. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N. Engl. J. Med. 337:1029-35
11. 11. Kontoyiannis D, Pasparakis M, Pizarro TT, et al. 1999. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10:387-98
12. 12. Present DH, Rutgeerts P, Targan S, et al. 1999. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340:1398-405
13. 13. Baert FJ, D'Haens GR, Peeters M, et al. 1999. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116:22-28
14. 14. Elson CO, Sartor RB, Tennyson GS, Riddell RH. 1995. Experimental models of inflammatory bowel disease. Gastroenterology 109:1344-67
15. 15. Takeda K, Clausen BE, Kaisho T, et al. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10:39-49
16. 16. Mizoguchi A, Mizoguchi E, Bhan AK. 1999. The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor alpha mutant mice. Gastroenterology 116: 320-26
17. 17. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. 1999. An open-label, stepwise dose-escalating pilot study to evaluate the safety, tolerance, and efficacy of low-dose thalidomide in the treatment of chronically-active, steroid-dependent Crohn's disease. Gastroenterology 116:G3637 (Abstr.)
18. 18. Kane SV, Ehrenpreis ED, Cohen LB, et al. 1999. Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease. Gastroenterology 116: G3234 (Abstr.)
19. 19. Stack WA, Mann SD, Roy AJ, et al. 1997. Randomised controlled trial of CDP571 antibody to tumor necrosis factor-α in Crohn's disease. Lancet 349:521-24
20. 20. van Dulleman HM, van Deventer SJH, Hommes DW, et al. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129-35
21. 21. Rutgeerts P, D'Haens G, van Deventer SJH, et al. 1997. Retreatment with anti-TNF-α chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Gastroenterology 112:A1078 (Abstr.)
22. 22. van Deventer SJ, Elson CO, Fedorak RN. 1997. Multiple doses of intravenous interleukin-10 in steroid refractory Crohn's disease. Gastroenterology 113: 383-89
23. 23. Schreiber S, Fedorak RN, Nielsen OH, et al. 1998. A safety and efficacy study of recombinant human interleukin-10 (rHuIL-10) treatment in 329 patients with chronic active Crohn's disease. Gastroenterology 114:G4423 (Abstr.)
24. 24. Dejaco C, Lichtenberger C, Reinisch W, et al. 1998. In vivo changes of lymphocyte subpopulations and leukocyte surface markers by multiple doses of recombinant human interleukin-10 in inflammatory bowel disease. Gastroenterology 114:G3939 (Abstr.)
25. 25. Fedorak RN, Gangl A, Elson CO, et al. 1998. Safety, tolerance and efficacy of multiple doses of subcutaneous interleukin-10 in mild to moderate active Crohn's disease. Gastroenterology 114:G3993 (Abstr.)
26. 26. Schreiber S, Fedorak RN, Wild G, et al. 1998. Safety and tolerance of rHuIL-10 treatment in patients with mild/moderate active ulcerative colitis. Gastroenterology 114:G4424 (Abstr.)
27. 27. Berg DJ, Davidson N, Kuhn R, et al. 1996. Enterocolitis and colon cancer in interleukin-10 deficient mice are associated with aberrant cytokine production and CD4+ Th1-like responses. J. Clin. Invest. 98:1010-20
28. 28. Kam LY, Vasiliauskas EA, Landers CJ, et al. 1999. Magnitude of response to Remicade® correlates with marker antibody expression. Gastroenterology 116: G3232 (Abstr.)